Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767624 · ClinicalTrials.gov registry record · Phase 2
TRIAD - Treatment of Insomnia and Depression
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00767624: Completed Phase 2 study, sponsored by Stanford University.
NCT00767624 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00767624, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy for Insomnia
- DRUG Antidepressant
- BEHAVIORAL Desensitization Therapy for Insomnia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2008-12 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00767624
The ClinicalTrials.gov registry entry for NCT00767624 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cognitive Behavioral Therapy for Insomnia is the first listed.
NCT00767624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00767624 about?
NCT00767624 is a clinical study titled "TRIAD - Treatment of Insomnia and Depression". The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.
What is the current status of trial NCT00767624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2008-12. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00767624?
The interventions under investigation include: Cognitive Behavioral Therapy for Insomnia (BEHAVIORAL), Antidepressant (DRUG), Desensitization Therapy for Insomnia (BEHAVIORAL).
Who is sponsoring clinical trial NCT00767624?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.